A recent study of 42 T2DM patients treated with the SGLT2 inhibitor dapagliflozin reported that dapagliflozin improved HRV and reduced the frequency of premature ventricular contractions, as compared to T2DM patients treated with other oral antidiabetics (non-SGLT2 inhibitor) [264]. Here, SLC5A2 is linked to type 2 diabetes mellitus.